Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
November 26, 2014, 01:53:05 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 647511
  • Total Topics: 49340
  • Online Today: 195
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Taking multi-targeted approaches to an HIV cure  (Read 952 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 162
Taking multi-targeted approaches to an HIV cure
« on: June 19, 2013, 01:17:04 AM »
May was a banner month for publications reporting on the progress of amfAR-funded researchers, with seven different teams reporting in five prestigious scientific journals. Four of these scientists led studies exploring two major themes in HIV cure research: eradication of HIV reservoirs, those silent pockets of virus that are impervious to current anti-HIV drugs; and pragmatic approaches to replicating the success of the "Berlin patient" through genetic engineering-based targeting of the CCR5 virus receptor.

First, reporting in Current Opinion in HIV and AIDS, Dr. Keith Jerome of the Fred Hutchinson Cancer Research Center in Seattle, Washington, a member of the amfAR-supported ARCHE consortium, described specific genetic engineering tools that can disrupt CCR5, a key entry point for HIV infection of a cell. This was the gene naturally altered in the donor whose bone marrow was transplanted into the "Berlin patient." The transplant was most likely a critical element in his cure. Most importantly, Dr. Jerome and his colleagues raise the prospect of a "one-shot" curative therapy, not requiring the expensive, technology-intensive, and risky procedures associated with a stem-cell transplant.

Another ARCHE member, Dr. Steven Deeks of the University of California-San Francisco (UCSF), and his colleagues at multiple institutions, including fellow amfAR grantees, Drs. Douek, Palmer, Pillai, J. Siliciano, R. Siliciano, and Richman, performed a comprehensive analysis of the "Berlin patient," who is now five years off all anti-HIV drugs. Writing in PLOS Pathogens, they confirm his clinical cure, while advocating the development of even more sensitive assays to detect various forms of HIV, active and latent, in order to facilitate documentation of potential HIV cures. This area of investigation is currently being explored by other amfAR-funded scientists.

On the issue of HIV latency and viral reservoirs untouchable by current drug strategies Dr. Hiroyu Hatano, also of UCSF, suggests that the overactive immune systems that characterize most HIV-positive individuals, on or off highly active antiretroviral therapy (HAART), may promote reservoir persistence. Dr. Hatano's review was published in Current Opinion in HIV and AIDS. She suggests interventions to treat co-infections and directly target immune activation.

Finally, amfAR grantee, Dr. Koh Fujinaga of UCSF and colleagues at the Chinese Academy of Sciences in Beijing describe a mechanism by which the reactivation of dormant HIV might be accomplished with anti-cancer drugs known as HDAC inhibitors. Dr. Fujinaga's work was published in the Journal of Biological Chemistry.

Finding a cure for HIV remains at the top of amfAR's research agenda. Along the path toward that goal, however, amfAR grantees are uncovering important information about the nature of the virus, which may lead to new, more effective treatment options in the future. As Dr. Jerome concluded in his report, such therapies "not only would give infected patients hope of a drug-free or treatment-free future, but also could reduce the huge financial burden faced by many countries because of widespread administration of highly active antiretroviral therapy."

http://sdgln.com/causes/2013/06/18/multi-targeted-approaches-hiv-cure



 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.